DexCom (NASDAQ:DXCM) Third Quarter 2022 Results
Key Financial Results- Revenue: US$769.6m (up 18% from 3Q 2021).
- Net income: US$101.2m (up 16% from 3Q 2021).
- Profit margin: 13% (in line with 3Q 2021).
- EPS: US$0.26 (up from US$0.23 in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
DexCom Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 5.9%.
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 26% from a week ago.
Risk Analysis
You still need to take note of risks, for example - DexCom has 1 warning sign we think you should be aware of.Valuation is complex, but we're here to simplify it.
Discover if DexCom might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.